Subject(s)
Urinary Bladder Neoplasms , Female , Humans , Male , Urinary Bladder , Urinary Bladder Neoplasms/diagnostic imagingSubject(s)
Humans , Male , Aged, 80 and over , Urinary Bladder Neoplasms/diagnosis , Palliative CareABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Carcinoma, Basal Cell/drug therapy , Imiquimod/administration & dosage , Skin Neoplasms/drug therapy , Administration, TopicalSubject(s)
Penile Diseases , Penile Induration , Humans , Male , Necrosis , Penile Diseases/surgery , Penile Erection , Penis , SkinABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Penile Diseases/surgery , Penile Diseases/pathology , NecrosisABSTRACT
72 year old female with a historyof breast cancer in remission, under study formonosymptomatic haematuria. Cystoscopy studyshows pigmented mucosal areas...
Paciente mujer de 72 años con antecedentede cáncer de mama en remisión, enestudio en urología por hematuria macroscópicamonosintomática. Se realiza cistoscopia observandoáreas de mucosa pigmentada...
Subject(s)
Urinary Bladder Neoplasms , Aged , Cystoscopy , Female , Hematuria , Humans , Urinary Bladder Neoplasms/diagnosisABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Urinary Bladder Neoplasms/diagnosis , Incidental Findings , Cystoscopy , Hematuria , Tomography, Emission-ComputedABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Urinary Sphincter, Artificial/adverse effects , Urologic Surgical Procedures, Male/methods , Prosthesis FailureSubject(s)
Urinary Sphincter, Artificial/adverse effects , Humans , Male , Middle Aged , Prosthesis FailureABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Penile Neoplasms/diagnostic imaging , Dysuria/etiology , Carcinoma, Verrucous/diagnostic imaging , Papillomaviridae/pathogenicityABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Varicocele/therapy , Embolization, Therapeutic , Low Back Pain/etiologySubject(s)
Back Pain/etiology , Embolization, Therapeutic/adverse effects , Varicocele/therapy , Adult , Humans , MaleABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Weight Gain/physiology , Magnetic Resonance Spectroscopy/methods , Cysts/pathology , Kidney Pelvis/metabolism , Urinary Retention/metabolism , Urinary Retention/pathology , Weight Gain/genetics , Magnetic Resonance Spectroscopy/standards , Cysts/complications , Kidney Pelvis/pathology , Urinary Retention/complications , Urinary Retention/diagnosisSubject(s)
Cysts/complications , Urinary Bladder Diseases/complications , Urinary Retention/etiology , Abdomen , Aged , Chronic Disease , Humans , MaleABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Cysts/metabolism , Cysts/pathology , Imaging, Three-Dimensional/methods , Urinary Tract Infections/metabolism , Urinary Tract Infections/urine , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/metabolism , Pelvic Infection/pathology , Cysts/rehabilitation , Cysts/surgery , Imaging, Three-Dimensional/instrumentation , Urinary Tract Infections/complications , Urinary Tract Infections/diagnosis , Prostatic Neoplasms/complications , Prostatic Neoplasms/genetics , Pelvic Infection/metabolismABSTRACT
OBJECTIVES: To study the efficacy and safety of the Perigee® System for the treatment of anterior vaginal prolapse in our experience with a medium term follow-up. METHODS: Prospective analysis on 48 consecutive patients with stage II-IV cystocele diagnosed from June 2006 until June 2009 using the Pelvic Organ Prolapse Quantitation classification without other associated prolapses. All diagnoses were done by a single urological specialist and follow-up is between 3 to 6 years. The questionnaire Patient Global Impression of Improvement was carried out before surgery, at the first follow up checking at one month, and at 6 and 12 months. The variables evaluated were age, presence of obesity, parity, prior hysterectomy, ASA class and stage of prolapse. RESULTS: The result, evaluating the questionnaire Patient Global Impression of Improvement, was cured or improved in 40 (83.3%) patients and 87.5% according to the Pelvic Organ Prolapse Quantitation, with a recurrence rate of 6.25%. Intraoperative complications were observed in 12.5% of the patients, postoperative in 4.2% and 41.5% after hospital discharge, pain being the most common complication (16.6%). The key variables for procedural failure were age 65 years >, obesity, parity ≥ 2, prolapse stage ≥ III and prior hysterectomy (p <0.05). CONCLUSIONS: In our series the Perigee® System allows anatomic repair with less morbidity, hospital stay and recovery time.
Subject(s)
Pelvic Organ Prolapse/surgery , Surgical Mesh , Age Factors , Aged , Cystocele/surgery , Female , Follow-Up Studies , Humans , Intraoperative Complications/epidemiology , Middle Aged , Obesity/complications , Parity , Patient Satisfaction , Postoperative Complications/epidemiology , Prospective Studies , Recurrence , Surveys and Questionnaires , Treatment OutcomeABSTRACT
OBJETIVO: Estudiar la eficacia y seguridad según nuestra experiencia del sistema Perigee® para el tratamiento del prolapso vaginal anterior. MÉTODOS: Análisis prospectivo en 48 pacientes consecutivas diagnosticadas mediante la clasificación para la Pelvic Organ Prolapse Quantification (Cuantificación del Prolapso de órganos Pélvicos) (POP-Q) de cistocele estadios II a IV, sin otros prolapsos asociados, desde Junio de 2006 hasta Junio de 2009, realizados por un único urólogo especializado, con un seguimiento de 3 a 6 años. Se ha realizado el cuestionario Patient Global Impression of Improvement (Impresión Global de Mejora del Paciente) (PGI-I) antes de la cirugía, en el primer control al mes, a los 6 y 12 meses. Se evaluaron las variables edad, presencia de obesidad, número de partos, histerectomía previa, clase ASA y estadio de prolapso. RESULTADOS: El resultado, evaluando el cuestionario Patient Global Impression of Improvement, fue de curación o mejoría en 40 (83,3%) pacientes y según la Pelvic Organ Prolapse Quantitation del 87,5%, con una tasa de recidiva del 6,25%. Se observaron complicaciones intraoperatorias en el 12,5% de las pacientes, postoperatorias en el 4,2%, y postalta en 41,5%, siendo el dolor la complicación más frecuente (16,6%). Las variables determinantes del fracaso del procedimiento, estadísticamente significativas (p <0,05), fueron la edad >65 años, obesidad, número de partos ≥ 2, estadio del prolapso ≥ III e histerectomía previa. CONCLUSIONES: En nuestra serie el sistema Perigee® permite la reparación anatómica con menor morbilidad, estancia hospitalaria y tiempo de recuperación
OBJECTIVES: To study the efficacy and safety of the Perigee® System for the treatment of anterior vaginal prolapse in our experience with a medium term follow-up. METHODS: Prospective analysis on 48 consecutive patients with stage II-IV cystocele diagnosed from June 2006 until June 2009 using the Pelvic Organ Prolapse Quantitation classification without other associated prolapses. All diagnoses were done by a single urological specialist and follow-up is between 3 to 6 years. The questionnaire Patient Global Impression of Improvement was carried out before surgery, at the first follow up checking at one month, and at 6 and 12 months. The variables evaluated were age, presence of obesity, parity, prior hysterectomy, ASA class and stage of prolapse. RESULTS: The result, evaluating the questionnaire Patient Global Impression of Improvement, was cured or improved in 40 (83.3%) patients and 87.5% according to the Pelvic Organ Prolapse Quantitation, with a recurrence rate of 6.25%. Intraoperative complications were observed in 12.5% of the patients, postoperative in 4.2% and 41.5% after hospital discharge, pain being the most common complication (16.6%). The key variables for procedural failure were age 65 years >, obesity, parity ≥ 2, prolapse stage ≥ III and prior hysterectomy (p <0.05). CONCLUSIONS: In our series the Perigee® System allows anatomic repair with less morbidity, hospital stay and recovery time
